 CAMBRIDGE, Mass. SALISBURY, England--BUSINESS WIRE--- KALV--KalVista Pharmaceuticals, Inc. NASDAQ: KALV, a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the second fiscal quarter ended October 31, 2020. We have completed the patient treatment phase of our KVD900 Phase 2 trial and are in the process of wrapping up that study. Data from 